Comparative Pharmacology
Head-to-head clinical analysis: PARASAL versus PARASAL SODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PARASAL versus PARASAL SODIUM.
PARASAL vs PARASAL SODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Uncertain; may involve inhibition of prostaglandin synthesis in the CNS, weak inhibition of COX-1 and COX-2, and activation of TRPA1 channels.
Parasal sodium is a prodrug that is converted to 5-aminosalicylic acid (5-ASA) in the colon, where it inhibits cyclooxygenase and lipoxygenase pathways, reducing prostaglandin and leukotriene synthesis, thereby exerting anti-inflammatory effects in the gastrointestinal tract.
4 g (8 capsules or 2 sachets) orally every 6 hours; maximum 16 g per day.
300 mg orally twice daily
None Documented
None Documented
Terminal half-life: 10-15 hours in adults with normal renal function; prolonged to 20-30 hours in renal impairment.
2-3 hours for low doses (antiplatelet effect); 15-30 hours for high doses (anti-inflammatory), increasing with dose due to saturation of hepatic metabolism.
Renal: 50-60% as unchanged drug; biliary/fecal: 20-30% as metabolites; total recovery: >80% within 24 hours.
Primarily renal (90-95% as unchanged drug and metabolites, with 50-70% as unchanged salicylate in alkaline urine); minor biliary (2-5%) and fecal (<1%).
Category C
Category C
Antituberculosis Agent
Antituberculosis Agent